Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Carcinoma, Non-Small-Cell Lung
Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (Funded by Bristol-Myers Squibb; CheckMate 057 ClinicalTrials.gov number, NCT01673867.).